Abivax (ABVX) Cash from Financing Activities (2024 - 2026)
Abivax (ABVX) posted quarterly Cash from Financing Activities of $85464.4 for Q1 2026, up 101.04% year-over-year from $42511.8 in Q1 2025, and up 100.19% quarter-over-quarter from -$46.0 million in Q4 2025.
Abivax (ABVX) Cash from Financing Activities (2024 - 2026) Analysis & Trends
Abivax's Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $85464.4 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 101.04% year-over-year to $85464.4; the TTM figure through Mar 2026 stood at $649.6 million (up 82091.53% YoY), while the FY2025 annual figure was $637.1 million, up 2014.13% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $85464.4, up from -$46.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $705.5 million in Q3 2025, with the low at -$46.0 million in Q4 2025.
- The 3-year median for Cash from Financing Activities is -$6.2 million (2024), against an average of $74.6 million.
- Peak annual rise in Cash from Financing Activities reached 10314.41% in 2025, while the deepest fall reached 638.73% in 2025.
- Abivax's Cash from Financing Activities stood at -$6.2 million in 2024, then tumbled by 638.73% to -$46.0 million in 2025, then jumped by 100.19% to $85464.4 in 2026.
- Business Quant data shows ABVX's Cash from Financing Activities at $85464.4 in Q1 2026, -$46.0 million in Q4 2025, and $705.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 85,464.43 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 85,464.43 |
| Mar 31, 2026 | 85,464.43 |
| Dec 31, 2025 | -46.05 Mn |
| Dec 31, 2025 | -46.05 Mn |
| Sep 30, 2025 | 705.48 Mn |
| Sep 30, 2025 | 705.48 Mn |
| Jun 30, 2025 | -9.92 Mn |
| Jun 30, 2025 | -9.92 Mn |
| Mar 31, 2025 | -8.24 Mn |
| Mar 31, 2025 | -8.24 Mn |
| Dec 31, 2024 | -6.23 Mn |
| Dec 31, 2024 | -6.23 Mn |
| Sep 30, 2024 | -6.91 Mn |
| Sep 30, 2024 | -6.91 Mn |
| Jun 30, 2024 | 20.59 Mn |
| Jun 30, 2024 | 20.59 Mn |
| Mar 31, 2024 | 23.03 Mn |
| Mar 31, 2024 | 23.03 Mn |